Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study.
Jason AldredEric Freire-AlvarezAlexander V AmelinAngelo AntoniniBruno BergmansFilip BergquistManon BouchardKumar BudurCamille B CarrollKallol Ray ChaudhuriSusan R CriswellErik H DanielsenFlorin GandorJia JiaThomas E KimberHideki MochizukiWeining Z RobiesonAmy M SpiegelDavid G StandaertSaritha TalapalaMaurizio F FacherisVictor S C FungPublished in: Neurology and therapy (2023)